How weight loss drugs could impact stocks

Weight loss drugs, such as Novo Nordisk’s (NVO) Ozempic and Wegovy, continue to grow in popularity. With many brand and retailer CEOs signaling the hit to snack food sales, how will these drugs impact the packaged food industry? Morgan Stanley Equity Research Analyst Pam Kaufman joins Yahoo Finance Live to discuss. “We see long-term implications across the food ecosystem from the growing adoption of GLP-1 anti-obesity drugs,” Kaufman says, citing implications for packaged foods, restaurants, beverages, and food retail. “Our biopharma analysts expect drug use to grow fivefold over the next 12 years and project that about seven percent of the population is going to be on the drugs by 2023,” Kaufman notes. As these drugs impact people’s appetites, “they will have an impact on long-term demand for food consumption.” For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
Subscribe to Yahoo Finance: https://yhoo.it/2fGu5Bb
#youtube #yahoofinance #stockmarket
About Yahoo Finance:
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Yahoo Finance Plus: With a subscription to Yahoo Finance Plus get the tools you need to invest with confidence. Discover new opportunities with expert research and investment ideas backed by technical and fundamental analysis. Optimize your trades with advanced portfolio insights, fundamental analysis, enhanced charting, and more.
To learn more about Yahoo Finance Plus please visit: https://yhoo.it/33jXYBp

Connect with Yahoo Finance:
Get the latest news: https://yhoo.it/2fGu5Bb
Find Yahoo Finance on Facebook: http://bit.ly/2A9u5Zq
Follow Yahoo Finance on Twitter: http://bit.ly/2LMgloP
Follow Yahoo Finance on Instagram: http://bit.ly/2LOpNYz
Follow Yahoo Finance Premium on Twitter: https://bit.ly/3hhcnmV